DiaSorin confirms the ability of its molecular tests to identify Sars-cov-2 virus even against a new Omicron variant. The company announced this, to highlight how it “is using the new variant sequences available on the Gisaid database to perform in silico tests and verify the ability to identify the virus in all tests in the suite”.
Moreover, the characteristics of the set’s molecular tests ensure “effectiveness in identifying the virus in the presence of all variants that have emerged since the beginning of the pandemic,” adds DiaSorin.
DiaSorin continues its “continuous monitoring of Sars-CoV-2 variants through “analysis of genetic sequences that are recorded daily on available databases,” the company adds in a note. The monitoring aims to assess the ability to identify the virus with “special tests even in the face of various mutations, Thus ensuring its reliability.
Reproduction is reserved © Copyright ANSA
“Explorer. Devoted travel specialist. Web expert. Organizer. Social media geek. Coffee enthusiast. Extreme troublemaker. Food trailblazer. Total bacon buff.”
